Findings indicate that altering glucose metabolism in T cells boosts their therapeutic potential against melanoma, paving the ...

A phase 2 trial finds that for patients with HER2+ metastatic colorectal cancer, dual HER2-inhibitor therapy can be a similarly efficacious but less toxic alternative to EGFR inhibitor therapy.

First-line treatment with targeted therapies plus chemotherapy offered overall response benefits in BRAF V600E-mutant ...

Quotient Therapeutics, a biotech company founded in 2022, hopes to take this transatlantic model and commercialise it. Its main research lab is in Great Chesterford, a village just outside Cambridge, ...

Complete recombination map of the human-genome, a major step in genetics Scientists at deCODE genetics/Amgen have constructed ...

Received supportive FDA feedback on key elements of the potential ELI-002 Phase 3 study design, including dose, schedule, patient population and ...

Below is a detailed analysis of the two drugs secured by Cosmos Health. Abstract #1: ESTERS OF STEROIDAL LACTAM AND BIS (2-CHLOROETHYL) AMINOPHENOXY PROPANOIC ACID DERIVATIVES; Patent International ...

FoundationOne CDx is now FDA-approved as the first companion diagnostic for tovorafenib, enabling targeted treatment for ...

The American Cancer Society's latest cancer report shows both positive and concerning trends: overall cancer deaths are down but the number of women and young adults with cancer is up. The annual ...

A range of current precision oncology clinical trials are reliant on customized, targeted NGS-panel assays in order to ...

Jones, a cancer biologist ... of protection in the human esophagus. By middle age, many esophagus clones—often making up the bulk of esophagus tissue—have mutations disrupting a gene called ...